Given that GLP-1 receptor agonists have now been shown to reduce rates of cardiovascular mortality, non-fatal myocardial infarction and non-fatal stroke, it is likely that these cardiovascular benefits are mediated by GLP-1 [83]. This evidence concerns the gene GLP1R and stroke disorder.